The claim of entitlement to a compensable rating for left axillary adenopathy with rhomboid spasm prior to October 14, 2022, and higher than 20 percent thereafter, is remanded.

Board reasoning

The Board remands the claims for additional development, including new medical opinions on functional loss during flares and after repetitive use, and the ameliorative effects of medications. It notes the need for a muscle injury examination for the left axillary adenopathy with rhomboid spasm, and requests SSA records, updated VA treatment records, and appropriate examinations to assess current severity. The reasoning emphasizes due process and the necessity of complete medical evidence before adjudication, without resolving the underlying rating issues in this decision.